The publication of the Signatera test in a prestigious journal like JCO Precision Oncology enhances Natera's credibility in the oncology field. Given the test's potential to detect early recurrence in breast cancer, it could lead to increased adoption by healthcare providers, thereby increasing Natera's revenues and market share in the cancer diagnostics market. The long-term follow-up data from the EBLIS study further supports the test's effectiveness, likely contributing to its positive reception among oncologists and patients.